TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Taysha Gene Therapies Inc (TSHA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth and positive momentum in its Rett syndrome study, the technical indicators and options data suggest a lack of immediate upward momentum. Additionally, there are no strong proprietary trading signals or recent news catalysts to support a buy decision right now.
The MACD is negatively expanding, RSI is neutral at 43.74, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level (4.416) with support at 4.171 and resistance at 4.66, suggesting limited immediate upside.
Hedge funds have significantly increased their buying activity by 649.63% over the last quarter. Analysts have raised the price target to $11, citing momentum in the Rett syndrome study and alignment with the FDA.
Pre-market price is down by 0.69%. Technical indicators do not show a clear upward trend. Options data indicates higher put volume relative to calls, suggesting bearish sentiment.
In Q4 2025, revenue increased by 171.27% YoY to $5,485,000. Net income improved by 48.26% YoY but remains negative at -$27,851,000. EPS improved by 14.29% YoY to -0.08. Gross margin remains strong at 100%.
Wells Fargo maintains an Overweight rating and raised the price target from $8 to $11, expecting another year of outperformance driven by the Rett syndrome study.
